| 摘要 |
<p>The present invention relates to methods and compositions to evaluate or assess the response and/or side effects of a subject to particular therapeutic treatment. More particulary, the invention provides methods to determine the response and/or side effects of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies in situations where target neutralisation is desired without depletion of a target cell. The invention is based on a determination of the FCGR3A genotype of a subject. Preferably, the therapeutic antibodies are antibodies or proteins comprising Fc portions of the G4 subclass.</p> |
